Search

everythinglearnresearchcommunity

for

Search:↓

Exosomes are being discussed as a potential hair loss treatment, with some users skeptical about their effectiveness and stability. There is interest in different types of exosomes, including those derived from centella asiatica, and comparisons are made to other treatments like finasteride.

PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.

Diffuse hair loss is often linked to genetics but can also be due to health issues like thyroid problems and low vitamin or iron levels. Treatments include finasteride, minoxidil, and dutasteride, with some seeing improvements after addressing health issues.

Minoxidil, finasteride, and RU58841 are suggested for hair loss treatment. Supplements like biotin and saw palmetto may help but are not effective for androgenic alopecia.

Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.

Liquid minoxidil makes hair sticky and stiff; users suggest oral minoxidil or minoxidil foam as alternatives. Applying minoxidil four hours before showering can help with absorption.

PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.

The potential of using Verteporfin to prevent hair loss scars and possible regrowth, with two doctors currently testing it, although the price of a 15mg bottle is expensive.

Flax seeds may block DHT and prevent hair loss. Users discuss its potential benefits, with one noting it likely has negligible effects on hair but is good for the diet.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

A user with androgenic alopecia seeks advice on making topical spironolactone from pills due to poor reactions to the oral form and its unavailability in their country. They are looking for guidance on preparing it themselves.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

The user has been using finasteride for 7 months and is inquiring about Thrive's hair serum, which contains redensyl, procapil, and anagain, seeking feedback from others who have used it.

2% fucoidan alleviated AGA symptoms, promoted hair growth, and increased hair density in mice. Fucoidan is considered safe for humans as a supplement and topical skincare product, with potential therapeutic effects against AGA.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

The conversation discusses the failure of Phase 3 trials for the hair loss treatment KX-826, with no significant difference found between the drug and placebo. Some users express disappointment and skepticism, while others discuss alternative treatments like Minoxidil, finasteride, and RU58841.

A user is considering adding PRP and mesotherapy to their hair loss treatment and is deciding between two options: Promoitalia, which contains Phosphatidic acid, Riboflavin, and Superoxide dismutase, and the more expensive Melsmon, a human placenta derivative. They seek advice on which option to choose based on effectiveness and scientific backing.

Broccoli or sulforaphane supplements are unlikely to improve Minoxidil results due to the need for an unrealistically large dose. Tretinoin, micro-needling, and low-dose oral Minoxidil may be more effective for those lacking the necessary enzyme in the scalp.

Using Stemoxydine, a hair growth promoter, in conjunction with Fin and Minoxidil to help counter shedding induced by the latter two treatments. Another user also shared their experience of using Stemoxydine for three months along with dermastamp.

PP405 shows promise for hair regrowth, with new hairs observed in 66% of patients in just 27 days. The discussion also mentions Minoxidil, finasteride, and RU58841 as potential treatments.

Shiseido's Dermal Sheath Cup (DSC) Hair Multiplication treatment is now available in Japan. Users discuss the treatment's availability and cost.

Hair loss discussion mentions fibers like toppik becoming difficult to use and questions if there's a better alternative, such as a spray or dermmatch.

PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.

A user asked if collagen or hair growth supplements made their hair thicker. Another user suggested that Vitamin D might help if deficient.

The conversation discusses the synthesis and potential use of JXL069 and PP405 for hair loss treatment, with skepticism about their effectiveness and concerns about safety. Users mention that JXL069 has shown no results in hair growth, and there is confusion about its identity and effectiveness compared to PP405.

Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. Users share experiences and support, mentioning that many people face hair thinning.

Combining spironolactone with koshine might enhance the effect of blocking androgen receptors for hair loss treatment. The user suggests adding crushed spironolactone pills to koshine.

Hopeful treatments for hair loss, including Verteporfin, Androgen Receptor Degradation, and SCUBE3. These treatments offer potential solutions to slow or stop the effects of androgens on the scalp.

Hair follicle regenerative therapy is being developed, with clinical trials planned in Japan, potentially allowing for hair cloning and eliminating the need for treatments like finasteride. If successful, the treatment could be available in Japan by 2025, but widespread access and affordability may take longer.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.